---
title: >-
  Oral Mesalamine Use in Crohn's Disease After Implementation of the American
  College of Gastroenterology Guidelines: A TARGET-IBD Cohort Study.
description: >-
  Explore this publication on real-world evidence: Oral Mesalamine Use in
  Crohn's Disease After Implementation of the American College of
  Gastroenterology…
date: '2019-01-01'
category: Publications
tags:
  - ACG
  - Care
  - IBD
  - Health System Partner
  - Poster Presentation
  - R&D
  - Gastroenterology
canonical_url: >-
  https://www.pedestalhealth.com/resources/publications/acg/oral-mesalamine-use-in-crohn-s-disease-after--2019-acg/
source: Pedestal Health
license: © 2026 Pedestal Health. All rights reserved.
slug: oral-mesalamine-use-in-crohn-s-disease-after--2019-acg
id: 7pzKndCHeIrqVtDTu6rkie
contentType: article
---

## Challenge

Following the March 2018 ACG guideline explicitly recommending against oral mesalamine for CD, it was unknown how quickly—or whether—this recommendation would change real-world prescribing patterns in US academic and community gastroenterology practices.

## Solution

The TARGET-IBD registry was used to compare mesalamine use prevalence before and after the ACG guideline publication, identifying predictors of continued use and characterizing how the guideline affected prescribing in academic versus community settings.

## Impact

Demonstrating that mesalamine use in CD remained essentially unchanged after the 2018 ACG guideline—with colonic and inflammatory phenotypes most likely to remain on therapy—documents a significant guideline adherence gap, providing the evidence base for targeted prescriber education and quality improvement initiatives.